Company intelligence / Profile preview

Celtis Pharmaceuticals

Cheongju-si, Chungcheongbuk-do, South Korea

Ownership: Private
Employees: ~60
Development stage: Other

Overview

Celtis Pharmaceuticals is currently commercializing several incrementally modified drugs (IMDs) and generics in the South Korean market, specifically focusing on fixed-dose combinations for metabolic and circulatory disorders. Their clinical efforts primarily involve Phase 1 and bioequivalence studies for new combination therapies.

Therapeutic areas: EndocrinologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Celtis Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celtis Pharmaceuticals.

Explore the full profile